Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty

Mostafa Sajadian1, Ladan Alizadeh1, Mahmoud Ganjifard2

  • 1Atherosclerosis Prevention Research Center, Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Iran.

Galen Medical Journal
|September 1, 2021
PubMed

Insights

In-stent restenosis (ISR) after percutaneous coronary angioplasty (PCI) is a challenge. Stent site, length, hypertension, and diabetes are probable factors influencing ISR, requiring further research into other risks.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Research

Background:

  • Percutaneous coronary angioplasty (PCI) and stent implantation are standard treatments for coronary artery stenosis.
  • In-stent restenosis (ISR) remains a significant clinical challenge following these procedures.
  • The precise factors contributing to ISR are not fully elucidated, with conflicting evidence regarding coronary artery disease (CAD) factors.

Purpose of the Study:

  • To conduct a comprehensive review of potential factors influencing in-stent restenosis (ISR) in patients who have undergone PCI.
  • To synthesize current evidence on the relationship between various patient and procedural factors and the occurrence of ISR.

Main Methods:

  • A narrative review methodology was employed.
  • Extensive literature searches were performed across major scientific databases: PubMed, Web of Science, Scopus, and Google Scholar.
  • The search covered publications from January 1, 1990, to July 30, 2017, with a rigorous screening process resulting in the selection of 39 relevant papers.

Main Results:

  • The analysis identified the anatomical site and length of the implanted stent as highly probable factors associated with ISR.
  • Hypertension and diabetes mellitus were also confirmed as significant contributing factors to ISR.
  • The review highlighted the need for further investigation into other potential risk factors.

Conclusions:

  • Stent characteristics (site and length) and patient comorbidities (hypertension, diabetes) are key factors implicated in ISR development.
  • Additional research is warranted to explore the impact of genetic factors, obesity, chronic infections, and glycemic control (e.g., Hemoglobin A1C) on ISR.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
68
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
63
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
55
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
139
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
64